NMN vs NR for NAD+ precursor comparison

NR repeatedly increases whole-blood NAD+ dose-dependently; NMN (including MIB-626) also raises NAD+ in RCTs. No clear superiority across studies. ^{[1][2][5][7][8]}

Most RCTs are short and show neutral or modest secondary signals (e.g., gait/sleep with NMN; mixed results in PAD/MCI with NR). More/larger trials needed. ^[3][4][6]

NR elevates NAD+ within 1–2 weeks; NMN can raise metabolites within days and peak by ~4 weeks; MIB-626 shows rises within first days. ^[1][2][7][8]

Both appear well tolerated short-term, but NR has broader human safety data and GRAS; NMN's long-term dataset is smaller. ^{[1][2][5][11]}

NR chloride has FDA GRAS notice and NDI acknowledgments; reputable NSF-certified products exist. Retail NMN quality is inconsistent. ^[11][12][16]

FDA deemed NMN excluded as a dietary supplement (drug-exclusion clause); major retailers removed NMN. NR remains lawful as a supplement. ^[13][14][15]

Human data confirm oral NR bioavailability; NMN raises NAD+ and may use the SLC12A8 transporter (shown in mice; debated). Human head-to-head data lacking. ^{[1][5][9][10]}

NR has multiple standardized, widely stocked SKUs; NMN's availability limits and adulteration risk can reduce real delivered dose/value. ^[14][16]